This is a phase 3 study designed to evaluate whether the administration of ganciclovir
increases ventilator-free days in immunocompetent patients with sepsis associated acute
respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical
illness will effectively suppress CMV reactivation in CMV seropositive adults with
sepsis-associated acute respiratory failure thereby leading to improved clinical outcomes
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.